Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||KIT positive|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT positive||prostate neuroendocrine neoplasm||no benefit||Imatinib||Preclinical||Actionable||In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106).||27980106|
|KIT positive||gastrointestinal stromal tumor||sensitive||Imatinib||FDA approved||Actionable||In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in an overall response rate of 38% (56/147) and a median duration of response of 13 weeks in patients with metastatic or unresectable KIT-positive GIST (PMID: 12374669).||12374669 detail...|
|KIT positive||breast cancer||predicted - sensitive||Imatinib + Letrozole||Phase 0||Actionable||In a pilot trial, Gleevec (imatinib mesylate) and Femara (letrozole) combination treatment resulted in clinical partial response in 90% (9/10) and stable disease in 10% (1/10) of the evaluable patients with invasive hormone-sensitive breast cancer, 8 of the 13 enrolled patients had KIT-positive tumors (PMID: 18248884).||18248884|
|KIT positive||germ cell cancer||resistant||Imatinib||Phase II||Actionable||In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496).||16462496|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01222143||Phase Ib/II||Cytarabine + Etoposide + Mitoxantrone Nilotinib||Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia||Terminated|
|NCT00812240||Phase III||Masitinib Imatinib||A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment||Terminated|
|NCT02642016||Phase I||CDX-0158||A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors||Completed|